J Korean Med Sci.  2006 Oct;21(5):781-789. 10.3346/jkms.2006.21.5.781.

Biomedical Issues of Dietary fiber beta-Glucan

• Kim SY
• Song HJ
• Lee YY
• Cho KH
• Roh YK

• KMID: 1781892
• DOI: http://doi.org/10.3346/jkms.2006.21.5.781

Abstract

beta-Glucan is a polysaccharide in the form of fiber and the main element of fiber in grains such as barley, oats, yeast and mushrooms. Many studies have examined the efficacy of beta-Glucan in terms of the lipid lowering effects, blood sugar reduction, weight reduction, immune modulator, and anticarcinogenic effect. However, there is no comprehensive review article on the biomedical issues regarding beta-Glucan. The authors searched for systematic reviews and clinical experiments for each relevant topic and reviewed the biomedical effects of beta-Glucan, for the purpose of developing research strategies for the future.

Keyword

beta-Glucans; Cholesterol; Glucose; Weight Loss; Weight Reductions; Anticarcinogenic Agents

MeSH Terms

beta-Glucans/administration & dosage/*pharmacology/therapeutic use
Neoplasms/drug therapy
Infection/drug therapy
Humans
Dose-Response Relationship, Drug
Dietary Supplements
Dietary Fiber/administration & dosage/*pharmacology/therapeutic use
Cholesterol/blood
Body Weight/drug effects
Blood Glucose/analysis
Anticholesteremic Agents/pharmacology
Animals

Figure

• 

  Fig. 1 β-glucan from oat.

Reference

1. Hendler SS, Rorvik D. PDR for Nutritional Supplements. 2001. 1st ed. Thomson Healthcare.

2. Anderson JW, Gilinsky NH, Deakins DA, Smith SF, O'Neal DS, Dillon DW, Oeltgen PR. Lipid responses of hypercholesterolemic men to oat-bran and wheat-bran intake. Am J Clin Nutr. 1991. 54:678–683.

3. Institute of Medicine of the National Academies. Dietary reference intakes. Proposed definition of dietary fiber. 2001. Washington, DC: National Academies Press.

4. Institute of Medicine of the National Academies. Dietary reference intakes. Energy, carbohydrates, fiber, fat, fatty acids, cholesterol, protein and amino acids. 2002. Washington, DC: National Academies Press.

5. Wan K. Effects of lentinan of peripheral blood mononuclear cell expression of interleukin-2 receptor in patients with chronic hepatitis B in vivo and in vitro. Hunan Yi Ke Da Xue Xue Bao. 1998. 23:90–92.

6. Nakano T, Oka K, Hanba K, Morita S. Intratumoral administration of sizofiran activates Langerhans cell and T cell infiltration in cervical cancer. Clin Immunol Immunopathol. 1996. 79:79–86.

7. Kupfahl C, Geginat G, Hof H. Lentinan has a stimulatory effect on innate and adaptive immunity against murine Listeria monocytogenes infection. Int Immunopharmacol. 2006. 6:686–696.

8. Wakshull E, Brunke-Reese D, Lindermuth J, Fisette L, Nathans RS, Crowley JJ, Tufts JC, Zimmerman J, Mackin W, Adams DS. PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor. Immunopharmacology. 1999. 41:89–107.

9. Kournikakis B, Mandeville R, Brousseau P, Ostroff G. Anthrax-protective effects of yeast beta 1,3 glucans. MedGenMed. 2003. 5:1.

10. Sullivan R, Smith JE, Rowan NJ. Medicinal mushrooms and cancer therapy: translating a traditional practice into Western medicine. Perspect Biol Med. 2006. 49:159–170.

11. Beer MU, Arrigoni E, Amado R. Effects of oat gum on blood cholesterol levels in healthy young men. Eur J Clin Nutr. 1995. 49:517–522.

12. Bridges SR, Anderson JW, Deakins DA, Dillon DW, Wood CL. Oat bran increases serum acetate of hypercholesterolemic men. Am J Clin Nutr. 1992. 56:455–459.

13. Lia A, Hallmans G, Sandberg AS, Sundberg B, Aman P, Andersson H. Oat beta-glucan increases bile acid excretion and a fiber-rich barley fraction increases cholesterol excretion in ileostomy subjects. Am J Clin Nutr. 1995. 62:1245–1251.

14. Lia A, Andersson H, Mekki N, Juhel C, Senft M, Lairon D. Postprandial lipemia in relation to sterol and fat excretion in ileostomy subjects given oat-bran and wheat test meals. Am J Clin Nutr. 1997. 66:357–365.

15. Bourdon I, Yokoyama W, Davis P, Hudson C, Backus R, Richter D, Knuckles B, Schneeman BO. Postprandial lipid, glucose, insulin, and cholecystokinin responses in men fed barley pasta enriched with beta-glucan. Am J Clin Nutr. 1999. 69:55–63.

16. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999. 69:30–42.

17. Ripsin CM, Keenan JM, Jacobs DR Jr, Elmer PJ, Welch RR, Van Horn L, Liu K, Turnbull WH, Thye FW, Kestin M. Oat products and lipid lowering. A meta-analysis. JAMA. 1992. 267:3317–3325.

18. Braaten JT, Wood PJ, Scott FW, Wolynetz MS, Lowe MK, Bradley-White P, Collins MW. Oat beta-glucan reduces blood cholesterol concentration in hypercholesterolemic subjects. Eur J Clin Nutr. 1994. 48:465–474.

19. Lovegrove JA, Clohessy A, Milon H, Williams CM. Modest doses of beta-glucan do not reduce concentrations of potentially atherogenic lipoproteins. Am J Clin Nutr. 2000. 72:49–55.

20. Torronen R, Kansanen L, Uusitupa M, Hanninen O, Myllymaki O, Harkonen H, Malkki Y. Effects of an oat bran concentrate on serum lipids in free-living men with mild to moderate hypercholesterolaemia. Eur J Clin Nutr. 1992. 46:621–627.

21. Beer MU, Arrigoni E, Amado R. Effects of oat gum on blood cholesterol levels in healthy young men. Eur J Clin Nutr. 1995. 49:517–522.

22. Robitaille J, Fontaine-Bisson B, Couture P, Tchernof A, Vohl MC. Effect of an oat bran-rich supplement on the metabolic profile of overweight premenopausal women. Ann Nutr Metab. 2005. 49:141–148.

23. Karmally W, Montez MG, Palmas W, Martinez W, Branstetter A, Ramakrishnan R, Holleran SF, Haffner SM, Ginsberg HN. Cholesterol-lowering benefits of oat-containing cereal in Hispanic americans. J Am Diet Assoc. 2005. 105:967–970.

24. Kerckhoffs DA, Hornstra G, Mensink RP. Cholesterol-lowering effect of beta-glucan from oat bran in mildly hypercholesterolemic subjects may decrease when beta-glucan is incorporated into bread and cookies. Am J Clin Nutr. 2003. 78:221–227.

25. Leadbetter J, Ball MJ, Mann JI. Effects of increasing quantities of oat bran in hypercholesterolemic people. Am J Clin Nutr. 1991. 54:841–845.

26. De Groot AP, Luyken R, Pikaar NA. Cholesterol-lowering effect of rolled oats. Lancet. 1963. 2:303–304.

27. Reyna NY, Cano C, Bermudez VJ, Medina MT, Souki AJ, Ambard M, Nunez M, Ferrer MA, Inglett GE. Sweeteners and beta-glucans improve metabolic and anthropometrics variables in well controlled type 2 diabetic patients. Am J Ther. 2003. 10:438–443.

28. Davidson MH, Dugan LD, Burns JH, Bova J, Story K, Drennan KB. The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. A dose-controlled study. JAMA. 1991. 265:1833–1839.

29. Uusitupa MI, Ruuskanen E, Makinen E, Laitinen J, Toskala E, Kervinen K, Kesaniemi YA. A controlled study on the effect of beta-glucan-rich oat bran on serum lipids in hypercholesterolemic subjects: relation to apolipoprotein E phenotype. J Am Coll Nutr. 1992. 11:651–659.

30. Uusitupa MI, Miettinen TA, Sarkkinen ES, Ruuskanen E, Kervinen K, Kesaniemi YA. Lathosterol and other non-cholesterol sterols during treatment of hypercholesterolaemia with beta-glucan-rich oat bran. Eur J Clin Nutr. 1997. 51:607–611.

31. McIntosh GH, Whyte J, McArthur R, Nestel PJ. Barley and wheat foods: influence on plasma cholesterol concentrations in hypercholesterolemic men. Am J Clin Nutr. 1991. 53:1205–1209.

32. Lupton JR, Robinson MC, Morin JL. Cholesterol-lowering effect of barley bran flour and oil. J Am Diet Assoc. 1994. 94:65–70.

33. Behall KM, Scholfield DJ, Hallfrisch J. Lipids significantly reduced by diets containing barley in moderately hypercholesterolemic men. J Am Coll Nutr. 2004. 23:55–62.

34. Keogh GF, Cooper GJ, Mulvey TB, McArdle BH, Coles GD, Monro JA, Poppitt SD. Randomized controlled crossover study of the effect of a highly beta-glucan-enriched barley on cardiovascular disease risk factors in mildly hypercholesterolemic men. Am J Clin Nutr. 2003. 78:711–718.

35. Nicolosi R, Bell SJ, Bistrian BR, Greenberg I, Forse RA, Blackburn GL. Plasma lipid changes after supplementation with beta-glucan fiber from yeast. Am J Clin Nutr. 1999. 70:208–212.

36. Anderson JW, Randles KM, Kendall CW, Jenkins DJ. Carbohydrate and fiber recommendations for individuals with diabetes: a quantitative assessment and meta-analysis of the evidence. J Am Coll Nutr. 2004. 23:5–17.

37. Brand-Miller J, Hayne S, Petocz P, Colagiuri S. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2003. 26:2261–2267.

38. American Diabetes Association. Nutrition Principles and Recommendations in Diabetes. Diabetes Care. 2004. 27:Suppl 1. S36–S46.

39. Tapola N, Karvonen H, Niskanen L, Mikola M, Sarkkinen E. Glycemic responses of oat bran products in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2005. 15:255–261.

40. Jenkins AL, Jenkins DJ, Zdravkovic U, Wursch P, Vuksan V. Depression of the glycemic index by high levels of beta-glucan fiber in two functional foods tested in type 2 diabetes. Eur J Clin Nutr. 2002. 56:622–628.

41. Pick ME, Hawrysh ZJ, Gee MI, Toth E, Garg ML, Hardin RT. Oat bran concentrate bread products improve long-term control of diabetes: a pilot study. J Am Diet Assoc. 1996. 96:1254–1261.

42. Slavin JL. Dietary fiber and body weight. Nutrition. 2005. 21:411–418.

43. Li J, Kaneko T, Qin LQ, Wang J, Wang Y. Effects of barley intake on glucose tolerance, lipid metabolism, and bowel function in women. Nutrition. 2003. 19:926–929.

44. Juntunen KS, Niskanen LK, Liukkonen KH, Poutanen KS, Holst JJ, Mykkanen HM. Postprandial glucose, insulin, and incretin responses to grain products in healthy subjects. Am J Clin Nutr. 2002. 75:254–262.

45. Lissner L, Lindroos AK, Sjostrom L. Swedish obese subjects (SOS): an obesity intervention study with a nutritional perspective. Eur J Clin Nutr. 1998. 52:316–322.

46. Kimm SY. The role of dietary fiber in the development and treatment of childhood obesity. Pediatrics. 1995. 96:1010–1014.

47. Alfieri M, Pomerleau J, Grace DM, Anderson L. Fiber intake of normal weight, moderately obese and severely obese subjects. Obes Res. 1995. 3:541–547.

48. Liu S, Willett WC, Manson JE, Hu FB, Rosner B, Colditz G. Relation between changes in intakes of dietary fiber and grain products and changes in weight and development of obesity among middle-aged women. Am J Clin Nutr. 2003. 78:920–927.

49. Birketvedt GS, Aaseth J, Florholmen JR, Ryttig K. Long-term effect of fibre supplement and reduced energy intake on body weight and blood lipids in overweight subjects. Acta Medica (Hradec Kralove). 2000. 43:129–132.

50. Hays NP, Starling RD, Liu X, Sullivan DH, Trappe TA, Fluckey JD, Evans WJ. Effects of an ad libitum low-fat, high-carbohydrate diet on body weight, body composition, and fat distribution in older men and women: a randomized controlled trial. Arch Intern Med. 2004. 164:210–217.

51. Howarth NC, Saltzman E, Roberts SB. Dietary fiber and weight regulation. Nutr Rev. 2001. 59:129–139.

52. Babineau TJ, Marcello P, Swails W, Kenler A, Bistrian B, Forse RA. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg. 1994. 220:601–609.

53. Babineau TJ, Hackford A, Kenler A, Bistrian B, Forse RA, Fairchild PG, Heard S, Keroack M, Caushaj P, Benotti P. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch Surg. 1994. 129:1204–1210.

54. Betafectin Gastrointestinal Study Group. Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Arch Surg. 1999. 134:977–983.

55. Hamano K, Gohra H, Katoh T, Fujimura Y, Zempo N, Esato K. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass. Int J Immunopharmacol. 1999. 21:531–540.

56. de Felippe Junior J, da Rocha e Silva Junior M, Maciel FM, Soares Ade M, Mendes NF. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan). Surg Gynecol Obstet. 1993. 177:383–388.

57. Gordon M, Guralnik M, Kaneko Y, Mimura T, Goodgame J, DeMarzo C, Pierce D, Baker M, Lang W. A phase II controlled study of a combination of the immune modulator, lentinan, with didanosine (ddI) in HIV patients with CD4 cells of 200-500/mm³. J Med. 1995. 26:193–207.

58. Nakao I, Uchino H, Orita K, Kaido I, Kimura T, Goto Y, Kondo T, Takino T, Taguchi T, Nakajima T, Fujimoto S, Miyazaki T, Miyoshi A, Yachi A, Yoshida K, Ogawa N, Furue H. Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer-a randomized comparative study by an envelope method. Gan To Kagaku Ryoho. 1983. 10:1146–1159.

59. Furue H, Uchino H, Orita K, Kimura T, Goto Y, Kondo T, Sato S, Takino T, Taguchi T, Nakao I. Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer (the second report): a randomized controlled study. Gan To Kagaku Ryoho. 1985. 12:1272–1277.

60. Fujimoto S. Clinical efficacies of schizophyllan (SPG) on advanced gastric cancer. Nippon Geka Gakkai Zasshi. 1989. 90:1447–1450.

61. Kanagawa Lentinan Research Group. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Hepatogastroenterology. 1999. 46:2662–2668.

62. Fujimoto S, Orita K, Kimura T, Kondo T, Taguchi T, Yoshida K, Ogawa N, Furue H. Clinical evaluation of SPG (schizophyllan) as a therapeutic adjuvant after surgery of gastric cancer: controlled study by an envelope method. Gan To Kagaku Ryoho. 1983. 10:1135–1145.

63. Fujimoto S, Furue H, Kimura T, Kondo T, Orita K, Taguchi T, Yoshida K, Ogawa N. Clinical evaluation of schizophyllan adjuvant immunochemotherapy for patients with resectable gastric cancer: a randomized controlled trial. Jpn J Surg. 1984. 14:286–292.

64. Fujimoto S, Furue H, Kimura T, Kondo T, Orita K, Taguchi T, Yoshida K, Ogawa N. Clinical outcome of postoperative adjuvant immunochemotherapy with sizofiran for patients with resectable gastric cancer: a randomised controlled study. Eur J Cancer. 1991. 27:1114–1118.

65. Taguchi T. Effects of lentinan in advanced or recurrent cases of gastric, colorectal, and breast cancer. Gan To Kagaku Ryoho. 1983. 10:387–393.

66. Wakui A, Kasai M, Konno K, Abe R, Kanamaru R, Takahashi K, Nakai Y, Yoshida Y, Koie H, Masuda H. Randomized study of lentinan on patients with advanced gastric and colorectal cancer. Tohoku Lentinan Study Group. Gan To Kagaku Ryoho. 1986. 13:1050–1059.

67. Miyazaki K, Mizutani H, Katabuchi H, Fukuma K, Fujisaki S, Okamura H. Activated (HLA-DR+) T-lymphocyte subsets in cervical carcinoma and effects of radiotherapy and immunotherapy with sizofiran on cell-mediated immunity and survival. Gynecol Oncol. 1995. 56:412–420.

68. Cooperative Study Group on SPG for Gynecological Cancer. Clinical effect of sizofiran combined with irradiation in cervical cancer patients: a randomized controlled study. Jpn J Clin Oncol. 1992. 22:17–25.

69. Okamura K, Suzuki M, Chihara T, Fujiwara A, Fukuda T, Goto S, Ichinohe K, Jimi S, Kasamatsu T, Kawai N. Clinical evaluation of sizofiran combined with irradiation in patients with cervical cancer. A randomized controlled study; a five-year survival rate. Biotherapy. 1989. 1:103–107.

70. Okamura K, Hamazaki Y, Yajima A. Adjuvant immunotherapy: two randomized controlled studies of patients with cervical cancer. Biomed Pharmacother. 1989. 43:177–181.

71. Okamura K, Suzuki M, Chihara T, Fujiwara A, Fukuda T, Goto S, Ichinohe K, Jimi S, Kasamatsu T, Kawai N. Clinical evaluation of schizophyllan combined with irradiation in patients with cervical cancer. A randomized controlled study. Cancer. 1986. 58:865–872.

72. Inoue M, Tanaka Y, Sugita N, Yamasaki M, Yamanaka T, Minagawa J, Nakamuro K, Tani T, Okudaira Y, Karita T. Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: a prospective randomized controlled study. Biotherapy. 1993. 6:13–18.

73. Tari K, Satake I, Nakagomi K, Ozawa K, Oowada F, Higashi Y, Negishi T, Yamada T, Saito H, Yoshida K. Effect of lentinan for advanced prostate carcinoma. Hinyokika Kiyo. 1994. 40:119–123.

74. Kosaka A, Kuzuoka M, Yamafuji K, Imaizumi A, Hattori Y, Yamashita A. Synergistic action of lentinan (LNT) with endocrine therapy of breast cancer in rats and humans. Gan To Kagaku Ryoho. 1987. 14:516–522.